Colchester Institute

January 1, 2026, marks the official start of Medicare directly negotiating prices for the first 10 high-impact medications. To manage this, a new entity called the Medicare Transaction Facilitator (MTF) has been established to handle the complex rebate and data exchange between pharmacies and manufacturers.

For pharmacies, this change brings significant financial pressure. Because reimbursement is now capped at the Maximum Fair Price (MFP) plus a modest dispensing fee, many retail pharmacies are struggling to cover their overhead. This document highlights the risk that some pharmacies may stop stocking these high-cost medications, potentially creating new access gaps for seniors in certain regions.

The most significant change in hospital operations this year is the transition from manual inventory management to AI-Driven Autonomous Replenishment. Hospitals have replaced weekly manual counts with camera-based systems and weight-sensitive shelving

.

AI algorithms now analyze real-time usage data, seasonal trends, and even local weather patterns (to predict respiratory or flu-related surges) to trigger automatic reorders. This shift has virtually eliminated the "stock-out" crisis, ensuring that critical lifesaving supplies are never missing during an emergency while simultaneously reducing overstock waste by up to 30%.

A major regulatory milestone in 2026 is the expansion of the FDA’s Novel Excipient Review Pilot Program. Traditionally, pharmaceutical companies were afraid to use "new" excipients because they weren't pre-approved, creating a cycle of stagnant innovation.

Under the 2026 guidelines, excipient manufacturers can submit their new molecules for safety review independently of a specific drug application. This has unlocked a wave of innovation in high-concentration subcutaneous delivery, allowing patients to self-inject large doses of medication at home that previously required hours-long hospital IV infusions.

While insulin pumps are popular, many patients in 2026 still prefer multiple daily injections (MDI) using pens. The MiniMed Go™ Smart MDI system, cleared by the FDA in January 2026, brings the intelligence of an insulin pump to those who use pens.

By pairing a smart insulin pen (like the InPen™) with a high-accuracy sensor (like the Instinct), the system tracks every injection and glucose reading in a single app. It provides automated alerts for missed doses and calculates the exact amount of insulin needed for meals. For the first time, pen users have access to the same powerful AI guidance that was previously exclusive to pump users.